Literature DB >> 19585379

Comparison of three rheumatoid arthritis disease activity scores in clinical routine.

B Rintelen1, J Sautner, P M Haindl, I Andel, A Maktari, B F Leeb.   

Abstract

OBJECTIVE: To evaluate whether the revised disease activity cut-off values for the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) are in congruence with the Disease Activity Score including a 28-joint count (DAS28) disease activity criteria in daily clinical routine. PATIENTS AND METHODS: A total of 570 rheumatoid arthritis (RA) outpatients were assessed and categorized according to the DAS28, the SDAI, and the CDAI. These results were compared to the respective DAS28 disease activity categories. Statistical evaluation was carried out by calculating alpha, the Spearman rank correlation, and kappa-statistics.
RESULTS: DAS28, SDAI, and CDAI levels were significantly correlated to one another on a group level (p < 0.001). Internal consistency was the highest for the CDAI (alpha = 0.783) and the lowest for the DAS28 (alpha = 0.664). Kappa-statistics revealed a substantial degree of agreement with respect to mild, moderate, and high disease activity according to the three scores, with exceptions concerning the definition of a remission-like state. Further categorization showed that an additional 44% of patients were found to be in remission according to the DAS28 disease activity criteria relative to those defined by the SDAI or the CDAI disease activity categories respectively.
CONCLUSION: The revised SDAI limits for disease activity and the respective CDAI thresholds proved to be in congruence with the DAS28 disease activity categories in daily clinical routine. The SDAI and the CDAI were found to be more stringent in defining remission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19585379     DOI: 10.1080/03009740902932835

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

1.  SASDAS (simplified version of ankylosing spondylitis disease activity score)-ESR performance and development of SASDAS-CRP and their agreement with ASDAS-ESR and ASDAS-CRP in patients with ankylosing spondylitis.

Authors:  Emilce Edith Schneeberger; Natalia Zamora; Gustavo Citera
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

2.  Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.

Authors:  Fabio Massimo Perrotta; Antonia De Socio; Silvia Scriffignano; Ennio Lubrano
Journal:  Clin Rheumatol       Date:  2018-02-21       Impact factor: 2.980

3.  Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.

Authors:  Gábor Futó; Attila Somogyi; Zoltán Szekanecz
Journal:  Clin Rheumatol       Date:  2014-03-06       Impact factor: 2.980

4.  Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience.

Authors:  H Singh; H Kumar; R Handa; P Talapatra; S Ray; V Gupta
Journal:  Arthritis       Date:  2011-12-29

5.  Health-related quality of life and disease activity in rheumatoid arthritis.

Authors:  Gholam Hossein Alishiri; Noushin Bayat; Ahmad Salimzadeh; Amirhossein Salari; Seyed Morteza Hosseini; Shadi Rahimzadeh; Shervin Assari
Journal:  J Res Med Sci       Date:  2011-07       Impact factor: 1.852

6.  The Reliability of Disease Activity Score in 28 Joints-C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters: A Cross-sectional, Exploratory Study.

Authors:  Inger Marie Jensen Hansen; Rikke Asmussen Andreasen; Mark Nam van Bui Hansen; Amir Emamifar
Journal:  J Clin Rheumatol       Date:  2017-03       Impact factor: 3.517

7.  Validation of a machine learning approach to estimate Clinical Disease Activity Index Scores for rheumatoid arthritis.

Authors:  Alison K Spencer; Jigar Bandaria; Michelle B Leavy; Benjamin Gliklich; Zhaohui Su; Gary Curhan; Costas Boussios
Journal:  RMD Open       Date:  2021-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.